August 7, 2020
Shortly before news broke that Teladoc was set to acquire Livongo, the chronic disease management company announced its quarterly earnings results. On Aug. 5 it announced that its second quarter total revenue came in at $91.9 million, which was up 125% YoY. The company reported a GAAP gross margin of 76.6% and non-GAAP gross margin of 77.3%.
The company attributed the gains to its growing...
July 31, 2020
Dexcom President and CEO Kevin Sayer is “incredibly proud” of what the company is calling “resilient growth” in the second quarter of 2020, according to an earnings call on Tuesday.
Despite having some uncertainty in the impacts of the COVID-19 pandemic, Dexcom was able to produce significant year-over-year growth in Q2 2020.
Sayer attributes much of the growth to a steady increase in knowledge...
July 27, 2020
Anthem has released its COVID-19-tracking and predictive digital platform, C19 Explorer, in partnership with CloudMedx. The tool has five data categories: public health, hospital, economy, social and preventative.
Users can view information on a national, state, county and city level with data on cases, deaths, unemployment, food insecurity and testing. C19 Explorer also includes future hot spot...
June 22, 2020
For years, Dexcom has been one of the leading competitors in the continuous glucose monitoring space. While the company is focused on looking ahead, that’s not to say there haven’t been some bumps in the road along the way.
In 2018, its Dexcom G6, an integrated continuous glucose monitoring system, got the green light from the FDA, making it the first interoperable CGM to get the designation....
June 19, 2020
When it comes to the diabetes space, Dexcom is one of the heavy hitters. Its work in the continuous glucose monitoring space has put it on the map. In 2018, its Dexcom G6, an integrated continuous glucose monitoring system, got the greenlight from the FDA, making it the first interoperable CGM to get the designation. This means that it could be part of an integrated system compatible with other...
June 17, 2020
Consumer virtual health and wellness brand Ro highlighted a new partnership with healthcare API company Ribbon Health that will help users and their virtual providers seek out in-person primary and specialty care services in their area. Accessible within the telehealth platform, the new capability is available across the U.S., and includes information on the types of insurance accepted at each...
May 8, 2020
This quarter Dexcom raked in $405 million in revenue, compared to $280.5 million in 2019’s Q1. This represents a 44% increase year over year (YoY), and beats the company's revenue goal by $46.7 million. Dexcom attributes its success to its growing user rate.
The gross profits from Q1 were $258.7 million. However, operating expenses have increased, coming in at $215.4 million in 2020 Q1, versus $...
March 12, 2020
Together in perfect harmony. Dexcom and Welldoc have kicked off a new collaboration that will provide Dexcom G6 continuous glucose monitor users with data-analysis insights from Welldoc's digital diabetes management product, BlueStar. These insights include information on how lifestyle factors such as activity, nutrition, sleep and medication adherence are affecting a user's glucose levels.
February 20, 2020
Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated Insulin Delivery System which uses a tubeless, wearable “Pod” to deliver insulin for 72 hours at a time.
Abbott and Insulet have partnered to offer a new integrated digital health platform that will...
January 21, 2020
One of the biggest digital health success stories of the two decades is in the diabetes space, especially the continuous glucose monitor (or CGM). The first CGM was approved by the FDA in 1999, but in the last decade we've seen CGMs become smaller, longer lasting and more comfortable, and we've seen huge strides in datasharing as CGM-phone connectivity went from novelty to commodity.